Saturday, July 21, 2018 9:56:42 PM
Company Name-Momenta Pharmaceuticals
Dates Employed
Jan 2011 – Present
Employment Duration
7 yrs 7 mos
Location
Cambridge, MA
Drove deals with CSL to create a collaboration for Momenta's novel autoimmune disease candidate M230, and Mylan and Baxter (Baxalta) in biosimilars. Each transaction involved out-partnering Momenta programs in multi-product collaboration opportunities.
In 2011, Momenta acquired the assets of Virdante Pharmaceuticals, a private biotechnology company based in Cambridge, MA. These assets form the basis of Momenta’s efforts to develop new drug programs focused on sialylating the Fc region of antibodies, including IVIG. Subsequently, Momenta partnered with AnaptysBio to develop antibodies which form the basis for a new drug development program for Momenta.
Judging from the *range and period he sold his shares, it is pre-arranged. Like you Jbog, this guy is pretty darn smart (Harvard) and works hard.... He would not be making this kind of trading mistake. I bet if it isn't pre-arranged he would hold and sell at the $100 range.
*Last 4 are July transactions... July 9,16,17,19.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM